These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 28420722)

  • 1. Low Tumor Mitochondrial DNA Content Is Associated with Better Outcome in Breast Cancer Patients Receiving Anthracycline-Based Chemotherapy.
    Weerts MJA; Hollestelle A; Sieuwerts AM; Foekens JA; Sleijfer S; Martens JWM
    Clin Cancer Res; 2017 Aug; 23(16):4735-4743. PubMed ID: 28420722
    [No Abstract]   [Full Text] [Related]  

  • 2. HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil.
    Di Leo A; Gancberg D; Larsimont D; Tanner M; Jarvinen T; Rouas G; Dolci S; Leroy JY; Paesmans M; Isola J; Piccart MJ
    Clin Cancer Res; 2002 May; 8(5):1107-16. PubMed ID: 12006526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data.
    Di Leo A; Desmedt C; Bartlett JM; Piette F; Ejlertsen B; Pritchard KI; Larsimont D; Poole C; Isola J; Earl H; Mouridsen H; O'Malley FP; Cardoso F; Tanner M; Munro A; Twelves CJ; Sotiriou C; Shepherd L; Cameron D; Piccart MJ; Buyse M;
    Lancet Oncol; 2011 Nov; 12(12):1134-42. PubMed ID: 21917518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CDO1 promoter methylation is a biomarker for outcome prediction of anthracycline treated, estrogen receptor-positive, lymph node-positive breast cancer patients.
    Dietrich D; Krispin M; Dietrich J; Fassbender A; Lewin J; Harbeck N; Schmitt M; Eppenberger-Castori S; Vuaroqueaux V; Spyratos F; Foekens JA; Lesche R; Martens JW
    BMC Cancer; 2010 Jun; 10():247. PubMed ID: 20515469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.
    ; Tanner M; Isola J; Wiklund T; Erikstein B; Kellokumpu-Lehtinen P; Malmström P; Wilking N; Nilsson J; Bergh J
    J Clin Oncol; 2006 Jun; 24(16):2428-36. PubMed ID: 16682728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor tissue levels of Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) and outcome following adjuvant chemotherapy in premenopausal lymph node-positive breast cancer patients: A retrospective study.
    Schrohl AS; Look MP; Meijer-van Gelder ME; Foekens JA; Brünner N
    BMC Cancer; 2009 Sep; 9():322. PubMed ID: 19744322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of the outcomes of non-randomised chemotherapy regimens in node positive breast cancer.
    Kuru B; Camlibel M; Dinc S; Gulcelik MA; Atalay C; Alagol H
    J Exp Clin Cancer Res; 2005 Sep; 24(3):363-72. PubMed ID: 16270522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing the impact of CMF-like/Anthracycline-based/Anthracycline-Taxane-based/dose-dense chemotherapy in dependency of positive axillary lymph nodes/hormone receptor-status/grading/T-stage on survival - A retrospective multi-centre cohort study of 3677 patients receiving adjuvant chemotherapy.
    Schwentner L; Wöckel A; König J; Janni W; Blettner M; Kreienberg R; Van Ewijk R;
    Eur J Cancer; 2014 Nov; 50(17):2905-15. PubMed ID: 25239681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of different neoadjuvant chemotherapy regimens on locally advanced breast cancer.
    Coskun U; Gunel N; Onuk E; Yilmaz E; Bayram O; Yamac D; Cihan A; Ucan B; Yildirim Y; Celenkoglu G; Ozkan S
    Neoplasma; 2003; 50(3):210-6. PubMed ID: 12937855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitochondrial DNA content in breast cancer: Impact on in vitro and in vivo phenotype and patient prognosis.
    Weerts MJ; Sieuwerts AM; Smid M; Look MP; Foekens JA; Sleijfer S; Martens JW
    Oncotarget; 2016 May; 7(20):29166-76. PubMed ID: 27081694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrospective analysis of the impact of anthracycline dose reduction and chemotherapy delays on the outcomes of early breast cancer molecular subtypes.
    Liutkauskiene S; Grizas S; Jureniene K; Suipyte J; Statnickaite A; Juozaityte E
    BMC Cancer; 2018 Apr; 18(1):453. PubMed ID: 29678165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of mitochondrial DNA content in peripheral blood with cancer-related fatigue and chemotherapy-related cognitive impairment in early-stage breast cancer patients: a prospective cohort study.
    Chae JW; Chua PS; Ng T; Yeo AHL; Shwe M; Gan YX; Dorajoo S; Foo KM; Loh KW; Koo SL; Chay WY; Tan TJY; Beh SY; Lim EH; Lee GE; Dent R; Yap YS; Ng R; Ho HK; Chan A
    Breast Cancer Res Treat; 2018 Apr; 168(3):713-721. PubMed ID: 29313215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.
    Francis P; Crown J; Di Leo A; Buyse M; Balil A; Andersson M; Nordenskjöld B; Lang I; Jakesz R; Vorobiof D; Gutiérrez J; van Hazel G; Dolci S; Jamin S; Bendahmane B; Gelber RD; Goldhirsch A; Castiglione-Gertsch M; Piccart-Gebhart M;
    J Natl Cancer Inst; 2008 Jan; 100(2):121-33. PubMed ID: 18182617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: results from the GEICAM/2003-02 study.
    Martín M; Ruiz A; Ruiz Borrego M; Barnadas A; González S; Calvo L; Margelí Vila M; Antón A; Rodríguez-Lescure A; Seguí-Palmer MA; Muñoz-Mateu M; Dorca Ribugent J; López-Vega JM; Jara C; Espinosa E; Mendiola Fernández C; Andrés R; Ribelles N; Plazaola A; Sánchez-Rovira P; Salvador Bofill J; Crespo C; Carabantes FJ; Servitja S; Chacón JI; Rodríguez CA; Hernando B; Álvarez I; Carrasco E; Lluch A
    J Clin Oncol; 2013 Jul; 31(20):2593-9. PubMed ID: 23733779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mitochondrial DNA content as a potential marker to predict response to anthracycline in breast cancer patients.
    Hsu CW; Yin PH; Lee HC; Chi CW; Tseng LM
    Breast J; 2010; 16(3):264-70. PubMed ID: 20408822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial.
    Bartlett JM; Munro A; Cameron DA; Thomas J; Prescott R; Twelves CJ
    J Clin Oncol; 2008 Nov; 26(31):5027-35. PubMed ID: 18768436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant chemotherapy in early breast cancer.
    Ejlertsen B
    Dan Med J; 2016 May; 63(5):. PubMed ID: 27127018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Pathologic Response Evaluation Systems after Anthracycline with/without Taxane-Based Neoadjuvant Chemotherapy among Different Subtypes of Breast Cancers.
    Lee HJ; Park IA; Song IH; Kim SB; Jung KH; Ahn JH; Ahn SH; Kim HH; Gong G
    PLoS One; 2015; 10(9):e0137885. PubMed ID: 26394326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial.
    Mackey JR; Martin M; Pienkowski T; Rolski J; Guastalla JP; Sami A; Glaspy J; Juhos E; Wardley A; Fornander T; Hainsworth J; Coleman R; Modiano MR; Vinholes J; Pinter T; Rodríguez-Lescure A; Colwell B; Whitlock P; Provencher L; Laing K; Walde D; Price C; Hugh JC; Childs BH; Bassi K; Lindsay MA; Wilson V; Rupin M; Houé V; Vogel C;
    Lancet Oncol; 2013 Jan; 14(1):72-80. PubMed ID: 23246022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utilization of fluorescence in situ hybridization with cytokeratin discriminators in TOP2A assessment of chemotherapy-treated patients with breast cancer.
    Pierceall WE; Sprott KM; Heikkinen T; Heikkila P; Alaparthi L; Aittomaki K; Al-Adhami M; Villegas-Bergazzi V; Meyer JL; Kutok JL; Bartkova J; Bartek J; Nevanlinna H; Weaver DT; Blomqvist C
    Hum Pathol; 2012 Sep; 43(9):1363-75. PubMed ID: 22204715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.